Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis.
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
27
06
2021
revised:
03
12
2021
accepted:
13
12
2021
pubmed:
5
3
2022
medline:
15
3
2022
entrez:
4
3
2022
Statut:
ppublish
Résumé
The identification and appropriate management of people with advanced HIV disease is a key component in the HIV response. People with HIV who are hospitalised are at a higher risk of death, a risk that might persist after discharge. The aims of this study were to estimate the frequency of negative post-discharge outcomes, and to determine risk factors for such outcomes in people with HIV. Using a broad search strategy combining terms for hospital discharge and HIV infection, we searched MEDLINE via PubMed and Embase from Jan 1, 2003 to Nov 30, 2021 to identify studies reporting outcomes among people with HIV following discharge from hospital. We estimated pooled proportions of readmissions and deaths after hospital discharge using random-effects models. We also did subgroup analyses by setting, region, duration of follow-up, and advanced HIV status at admission, and sensitivity analyses to assess heterogeneity. We obtained data from 29 cohorts, which reported outcomes of people living with HIV after hospital discharge in 92 781 patients. The pooled proportion of patients readmitted to hospital after discharge was 18·8% (95% CI 15·3-22·3) and 14·1% (10·8-17·3) died post-discharge. In sensitivity analyses, no differences were identified in the proportion of patients who were readmitted or died when comparing studies published before 2016 with those published after 2016. Post-discharge mortality was higher in studies from Africa (23·1% [16·5-29·7]) compared with the USA (7·5% [4·4-10·6]). For studies that reported both post-discharge mortality and readmission, the pooled proportion of patients who had this composite adverse outcome was 31·7% (23·9-39·5). Heterogeneity was moderate, and largely explained by patient status and linkage to care. Reported risk factors for readmission included low CD4 cell count at admission, longer length of stay, discharge against medical advice, and not linking to care following discharge; inpatient treatment with antiretroviral therapy (ART) during hospitalisation was protective of post-discharge mortality. More than a quarter of patients with HIV had an adverse outcome after hospital discharge with no evidence of improvement in the past 15 years. This systematic review highlights the importance of ensuring post-discharge referral and appropriate management, including ART, to reduce mortality and readmission to hospital among this group of high-risk patients. Bill & Melinda Gates Foundation. For the French and Spanish translations of the abstract see Supplementary Materials section.
Sections du résumé
BACKGROUND
The identification and appropriate management of people with advanced HIV disease is a key component in the HIV response. People with HIV who are hospitalised are at a higher risk of death, a risk that might persist after discharge. The aims of this study were to estimate the frequency of negative post-discharge outcomes, and to determine risk factors for such outcomes in people with HIV.
METHODS
Using a broad search strategy combining terms for hospital discharge and HIV infection, we searched MEDLINE via PubMed and Embase from Jan 1, 2003 to Nov 30, 2021 to identify studies reporting outcomes among people with HIV following discharge from hospital. We estimated pooled proportions of readmissions and deaths after hospital discharge using random-effects models. We also did subgroup analyses by setting, region, duration of follow-up, and advanced HIV status at admission, and sensitivity analyses to assess heterogeneity.
FINDINGS
We obtained data from 29 cohorts, which reported outcomes of people living with HIV after hospital discharge in 92 781 patients. The pooled proportion of patients readmitted to hospital after discharge was 18·8% (95% CI 15·3-22·3) and 14·1% (10·8-17·3) died post-discharge. In sensitivity analyses, no differences were identified in the proportion of patients who were readmitted or died when comparing studies published before 2016 with those published after 2016. Post-discharge mortality was higher in studies from Africa (23·1% [16·5-29·7]) compared with the USA (7·5% [4·4-10·6]). For studies that reported both post-discharge mortality and readmission, the pooled proportion of patients who had this composite adverse outcome was 31·7% (23·9-39·5). Heterogeneity was moderate, and largely explained by patient status and linkage to care. Reported risk factors for readmission included low CD4 cell count at admission, longer length of stay, discharge against medical advice, and not linking to care following discharge; inpatient treatment with antiretroviral therapy (ART) during hospitalisation was protective of post-discharge mortality.
INTERPRETATION
More than a quarter of patients with HIV had an adverse outcome after hospital discharge with no evidence of improvement in the past 15 years. This systematic review highlights the importance of ensuring post-discharge referral and appropriate management, including ART, to reduce mortality and readmission to hospital among this group of high-risk patients.
FUNDING
Bill & Melinda Gates Foundation.
TRANSLATIONS
For the French and Spanish translations of the abstract see Supplementary Materials section.
Identifiants
pubmed: 35245507
pii: S2352-3018(21)00329-5
doi: 10.1016/S2352-3018(21)00329-5
pmc: PMC8905089
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e150-e159Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
HIV Med. 2016 Mar;17(3):167-77
pubmed: 26176492
PLoS One. 2019 Jan 30;14(1):e0210287
pubmed: 30699151
S Afr Med J. 2012 May 23;102(6):549-53
pubmed: 22668961
Lancet HIV. 2015 Oct;2(10):e438-44
pubmed: 26423651
J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):398-405
pubmed: 19186352
PLoS One. 2011 Feb 17;6(2):e14684
pubmed: 21379378
AIDS Res Hum Retroviruses. 2016 Aug;32(8):729-36
pubmed: 27005488
Open Forum Infect Dis. 2020 May 26;7(6):ofaa193
pubmed: 32550239
Open Forum Infect Dis. 2019 Jul 16;6(10):ofz336
pubmed: 31660330
Stat Methods Med Res. 1993;2(2):121-45
pubmed: 8261254
AIDS Care. 2021 Mar;33(3):306-310
pubmed: 31893942
BMC Health Serv Res. 2014 Dec 03;14:627
pubmed: 25465206
Medicine (Baltimore). 2015 Dec;94(50):e2269
pubmed: 26683950
Clin Infect Dis. 2020 Oct 23;71(7):1616-1623
pubmed: 31637434
AIDS. 2017 Apr;31 Suppl 1:S31-S40
pubmed: 28296798
J Gen Intern Med. 2021 May;36(5):1371-1379
pubmed: 33537953
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):407-12
pubmed: 26505329
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):522-530
pubmed: 27846069
Int J STD AIDS. 2015 Jun;26(7):467-9
pubmed: 25015932
Front Public Health. 2020 Feb 21;8:15
pubmed: 32154201
Pediatrics. 2019 Jan;143(1):
pubmed: 30552144
BMJ Open. 2018 Dec 28;8(12):e023445
pubmed: 30593550
S Afr Med J. 2018 Oct 02;108(10):870-875
pubmed: 30421717
HIV Med. 2021 Aug;22(7):557-566
pubmed: 33792151
Am J Clin Nutr. 2021 Mar 11;113(3):665-674
pubmed: 33471057
PLoS One. 2018 Dec 13;13(12):e0208429
pubmed: 30543667
PLoS One. 2013 Jun 25;8(6):e66698
pubmed: 23825556
Ann Intensive Care. 2012 Jul 04;2(1):25
pubmed: 22762133
J Assoc Nurses AIDS Care. 2017 Jan - Feb;28(1):95-104
pubmed: 27815018
PLoS One. 2019 Jul 3;14(7):e0218902
pubmed: 31269056
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):349-58
pubmed: 23095935
J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):e90-e98
pubmed: 28291051
JAMA. 2013 Jan 23;309(4):345-6
pubmed: 23340632
Int J STD AIDS. 2018 Jun;29(7):641-649
pubmed: 29402187
PLoS One. 2020 Sep 21;15(9):e0239452
pubmed: 32956419
Am J Trop Med Hyg. 2021 Oct 18;105(6):1662-1671
pubmed: 34662866
AIDS Patient Care STDS. 2015 Sep;29(9):465-73
pubmed: 26154066
BMC Health Serv Res. 2018 Apr 2;18(1):225
pubmed: 29606125
J Hosp Med. 2014 Nov;9(11):688-94
pubmed: 25130292
Int J STD AIDS. 2011 Aug;22(8):465-70
pubmed: 21795420
PLoS One. 2018 Feb 7;13(2):e0191944
pubmed: 29415015
J Crit Care. 2011 Feb;26(1):65-75
pubmed: 20716477
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):551-558
pubmed: 30204719
S Afr Med J. 2012 Nov 08;103(1):28-31
pubmed: 23237120
Clin Neurol Neurosurg. 2019 Nov;186:105539
pubmed: 31590063
Open Forum Infect Dis. 2019 Jan 19;6(2):ofz009
pubmed: 30740471